News
Blood donors’ genetic background affects hemolysis
ANAHEIM, CA—Interim results of a large study suggest a blood donor’s genetic background and frequency of donation influence red blood cell (RBC)...
News
Canada may shorten deferral for MSM blood donors
Photo by Charles Haymond ANAHEIM, CA—Lifting the lifetime ban on blood donations from men who have sex with men (MSM) has not altered the safety...
News
A better FLT3 inhibitor for AML?
© ASCO/Scott Morgan CHICAGO—A dual inhibitor of FLT3 and Axl may produce more durable responses than other FLT3 inhibitors and improve survival...
News
CAR produces high CR rate in adults with rel/ref ALL
the 2015 ASCO Annual Meeting © ASCO/Max Gersh CHICAGO—A CD19-targeted chimeric antigen receptor (CAR) T-cell therapy can provide durable complete...
News
No survival difference with allo- or auto-SCT in PTCL
© ASCO/Max Gersh CHICAGO—Allogeneic and autologous transplants produce similar survival rates when used as first-line therapy in younger patients...
News
Triplet shows early promise for relapsed CLL, NHL
©ASCO/Rodney White CHICAGO—A 3-drug combination is safe and highly active in certain patients with relapsed B-cell malignancies, according to a...
News
LSC phenotypes correlate with prognosis in AML
© ASCO/Rodney White CHICAGO—Researchers say they have identified 3 leukemia stem cell (LSC) phenotypes that are correlated with cytogenetic/...
News
Inhibitor promotes chemosensitization in CLL
PHILADELPHIA—A DNA-dependent protein kinase (DNA-PK) inhibitor can sensitize chronic lymphocytic leukemia (CLL) cells to chemotherapy, according...
News
Study helps explain how drug fights DLBCL
Their experiments showed that certain diffuse large B-cell lymphoma (DLBCL) cell lines were sensitive to CUDC-427, and others were not. However,...
News
Inhibitor may benefit certain ALL patients
In xenograft models of various ALL subtypes, ABT-199 produced an objective response rate below 30%. However, additional analyses unearthed...
News
Agent preferentially targets FLT3-ITD AML
PHILADELPHIA—Preclinical research suggests a novel agent has preferential activity in acute myeloid leukemia (AML) with FMS-like tyrosine kinase 3...
News
Defining the role of TAMs in DLBCL
pseudopodia to engulf particles PHILADELPHIA—New research suggests the prognostic value of tumor-associated macrophages (TAMs) is disease-...
News
Susceptibility to 2nd cancers in WM/LPL survivors
PHILADELPHIA—A retrospective study has revealed factors that appear to influence a person’s susceptibility to Waldenström’s macroglobulinemia (WM...
News
MKIs can overcome resistance in CML
PHILADELPHIA—Two multikinase inhibitors (MKIs) can treat chronic myeloid leukemia (CML) that is resistant to other inhibitors, according to...
News
Molecule increases TRAIL expression to fight NHL
Convention Center, site of the AACR Annual Meeting 2015 PHILADELPHIA—When current treatment approaches failed to save a young patient with non-...